utomilumab
Showing 1 - 8 of 8
Malignant Tumors of Ill-defined Secondary and Unspecified Sites, Malignant Tumors of Lip Oral Cavity and Pharynx, Oropharyngeal
Terminated
- Malignant Neoplasms of Ill-defined Secondary and Unspecified Sites
- +2 more
- Utomilumab
- ISA101b
-
Houston, TexasUniversity of Texas MD Anderson Cancer Center
Nov 22, 2022
COL6A3 Positive, HLA-A*0201 Positive Cells Present, PRAME Positive Trial in Houston (biological, drug, procedure)
Active, not recruiting
- COL6A3 Positive
- +3 more
- Aldesleukin
- +4 more
-
Houston, TexasM D Anderson Cancer Center
Sep 22, 2022
Metastatic Colorectal Carcinoma, Stage IV Colorectal Cancer AJCC v8, Stage IVA Colorectal Cancer AJCC v8 Trial in Houston
Active, not recruiting
- Metastatic Colorectal Carcinoma
- +4 more
- Cetuximab
- +3 more
-
Houston, TexasM D Anderson Cancer Center
Aug 4, 2022
HER2 Positive Breast Carcinoma, Recurrent Breast Carcinoma, Stage III Breast Cancer Trial in Palo Alto (Utomilumab, Trastuzumab,
Completed
- HER2 Positive Breast Carcinoma
- +6 more
- Utomilumab
- +2 more
-
Palo Alto, CaliforniaStanford University, School of Medicine
Sep 22, 2022
Follicular Lymphoma Trial in United States (Rituximab, Utomilumab, Avelumab)
Active, not recruiting
- Follicular Lymphoma
- Rituximab
- +3 more
-
Duarte, California
- +5 more
Mar 17, 2022
Advanced Malignancies, NSCLC, Ovarian Cancer Trial in Worldwide (Avelumab, Lorlatanib, Talazoparib)
Recruiting
- Advanced Malignancies
- +4 more
- Avelumab
- +7 more
-
Fayetteville, Arkansas
- +61 more
Jan 10, 2023
DLBCL Trial in Worldwide (biological, other, drug)
Terminated
- Diffuse Large B-Cell Lymphoma
- Avelumab
- +6 more
-
Duarte, California
- +29 more
Nov 20, 2020